Brilinta Market

Brilinta Market: Overview

The increasing rates of heart attacks and strokes has highly increased the popularity of Brilinta in the medical industry. According to the World Health Organization, approximately 17 million people die of cardiovascular diseases every year. This alarming number calls for a need to deploy a robust preventive measure. Moreover, brilinta also eliminates the risk of infection-related death. A study called Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor (XANTHIPPE) displayed considerable improvement in the lung function of the pneumonia patients using brilinta.

The rising popularity of brilinta among the physicians and patients has encouraged Transparency Market Research to conduct an in-depth research on the global brilinta market. In its latest study, TMR offers a comprehensive analysis of the market’s structure and shed light on the key growth dynamics. It highlights the growth scenario and competitive landscape of the market. Moreover, it states business strategies deployed by the key enterprises functioning in the global brilinta market and ascertains the challenges faced by them in the long run.

Brilinta Market: Notable Developments and Competitive Analysis

There are a very few players operating in the global brilinta market as the drug was approved a few years back. Listed below are a few notable developments in the market:

In June 2015, Sun Pharmaceutical Industries Ltd. collaborated with AstraZeneca Pharma India Limited (AZPIL), a leading manufacturer of brilinta. The agreement was aimed at enhancing the distribution network of “Axcer”, a new brand of ticagrelor drug. AZPIL already markets a ticagrelor drug under the trademark “Brilinta” in India. This collaboration helped Sun Pharmaceutical Industries to build a robust brand image by promoting the use of ticagrelor in India.

Brilinta Market: Key Drivers and Restraints

In recent times, there has been a steady rise in the development of ticagrelor drugs due to rising FDA approvals. Moreover, it has a greater efficacy as compared clopidogrel in the treatment of acute coronary syndrome. The results of the PLAT trial showed that patients treated with ticagrelor were less likely to die from stroke, vascular causes, and heart attack. These factors have highly contributed to expansion of the global brilinta market.

However, despite the numerous driving factors, there are a few restraints that may restrict the market’s growth. Side effects associated with ticagrelor use such as bleeding and dyspnea may discourage the use of ticagrelor. Nonetheless, development of new phararmaceutical compounds containing ticagrelor and rising awareness pertaining to the benefits of brilinta may propel the global brilinta market’s expansion.

Brilinta Market: Regional Analysis

Based on geography, the brilinta market is market is segmented into North America, Europe, China, and Japan.  Out of these, North America is anticipated to dominate the global brilinta market due to increase in expenditure on healthcare facilities and rising geriatric population. The U.S. holds a major share in the market’s growth in this region due to rising cases of cardiovascular disorders. The market in Europe is also anticipated to grow at a promising pace due to rising patient population and recent progression in the economy. Furthermore, introduction of advanced treatment options and government initiatives have contributed to the brilinta market’s growth in this region. The market in China and Japan is anticipated to grow at a steady pace due to rising concerns regarding cardiovascular diseases and increasing research pertaining to the development of new drugs.